TY - JOUR
T1 - Liposomal doxorubicin: the good, the bad and the not-so-ugly
AU - Szebeni, J.
AU - Fülöp, Gyula
AU - Dézsi, L.
AU - Metselaar, Josbert Maarten
AU - Storm, Gerrit
PY - 2016
Y1 - 2016
N2 - There are direct and indirect indications that PEGylated liposomal doxorubicin (Doxil), a widely used anticancer nanomedicine, has a subclinical immune suppressive effect. As an example of a seemingly bad pharmacological property turning out to be “not-so-ugly”, but actually beneficial, the authors highlight the potential benefits of Doxil's immune suppressive effect. These include (1) the decreased uptake of the drug by the MPS which may entail enhanced tumor uptake, and, hence, improved therapeutic efficacy; (2) the use of slow infusion protocols in reducing the risk of hypersensitivity (infusion) reactions; and (3), possible protection against hypersensitivity reactions to co-administered reactogenic drugs. To consider immune suppression as useful represents a paradigm shifts in nanotoxicology and anticancer chemotherapy.
AB - There are direct and indirect indications that PEGylated liposomal doxorubicin (Doxil), a widely used anticancer nanomedicine, has a subclinical immune suppressive effect. As an example of a seemingly bad pharmacological property turning out to be “not-so-ugly”, but actually beneficial, the authors highlight the potential benefits of Doxil's immune suppressive effect. These include (1) the decreased uptake of the drug by the MPS which may entail enhanced tumor uptake, and, hence, improved therapeutic efficacy; (2) the use of slow infusion protocols in reducing the risk of hypersensitivity (infusion) reactions; and (3), possible protection against hypersensitivity reactions to co-administered reactogenic drugs. To consider immune suppression as useful represents a paradigm shifts in nanotoxicology and anticancer chemotherapy.
KW - 2023 OA procedure
U2 - 10.3109/1061186X.2016.1172591
DO - 10.3109/1061186X.2016.1172591
M3 - Article
SN - 1061-186X
VL - 24
SP - 765
EP - 767
JO - Journal of drug targeting
JF - Journal of drug targeting
IS - 9
ER -